Trial Profile
Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients With Pneumonia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2012
Price :
$35
*
At a glance
- Drugs Doripenem (Primary)
- Indications Bacterial infections; Febrile neutropenia; Pneumonia
- Focus Pharmacokinetics
- 04 Jun 2012 Actual patient number is 12 as reported by ClinicalTrials.gov.
- 04 Jun 2012 Primary endpoints amended as reported by ClinicalTrials.gov.
- 04 Jun 2012 Actual end date (1 Feb 2012) added as reported by ClinicalTrials.gov.